Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 2c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.05), $0.02 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $280 thousand versus the consensus estimate of $28 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Braze Inc (BRZE) PT Raised to $33 at Raymond James, 'Buy the Dip as BRZE Remains a Secular Winner'
• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance